Clinical trials
Locally Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting locally advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 4,281 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07733180RecruitingPhase 2
Study of tislelizumab plus chemo for advanced esophageal cancer
This trial tests different schedules of tislelizumab (an immunotherapy drug) combined with chemotherapy for Japanese patients with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. It aims to find a better way to give these treatments together.
Yokohama, KanagawaAges 18 years+ - NCT07722494RecruitingPhase 3
Investigational drug plus bevacizumab for advanced colorectal cancer
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Wuhan, WuhanAges 18 years+ - NCT07723482RecruitingPhase 1/Phase 2
Study of ML-016 for cancer that has spread to lungs or liver
This trial tests a new drug called ML-016 in people whose advanced cancer has spread to their lungs or liver and who have run out of standard treatment options. The goal is to see if ML-016 can shrink tumors or slow the cancer's growth.
Miranda, New South WalesAges 18 years+ - NCT07710885RecruitingPhase 3
Futibatinib for advanced bile duct cancer
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
BrisbaneAges 18 years+ - NCT07713550Recruiting
Genetic profiling to guide treatment for advanced solid tumors
This study tests whether analyzing the DNA of your tumor (from a tissue sample or blood draw) can help find the best treatment for your advanced cancer. Researchers will look for genetic changes that could make you eligible for targeted therapy or a clinical trial.
AnderlechtAges 18 years+ - NCT06207656RecruitingPhase 2
Targeted therapy for BRAF V600E mutated colorectal cancer
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
MadridAges 18 years+ - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07692204RecruitingPhase 2
Testing a new drug for advanced stomach cancer
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
ShanghaiAges 18 years+ - NCT07681882RecruitingPhase 1
Testing DS1025a in people with advanced solid tumors
This trial tests a new drug, DS1025a, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
KashiwaAges 18 years+ - NCT07668037Recruiting
Understanding long-term survival in NSCLC immunotherapy
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
BeijingAges 18 years+ - NCT07667751RecruitingPhase 2
Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
HefeiAges 18–75 - NCT07655622RecruitingPhase 1/Phase 2
Vebreltinib and furmonertinib for advanced EGFR-mutant lung cancer with high PD-L1
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Nanchang, JianxiAges 18–75 - NCT07649928RecruitingEarly Phase 1
Testing ES502 for Advanced Pancreatic and Other Cancers
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07642375Recruiting
Digital Tools to Manage Sarcoma Treatment Side Effects
This study tests whether a digital app or online tool can help you better manage symptoms and side effects from your sarcoma treatment. Researchers want to see if tracking your symptoms online improves how you feel during cancer care.
AthensAges 18 years+ - NCT07645261RecruitingPhase 2
Lattice Radiation for Large Tumors When Other Treatments Won't Help
This trial tests a special type of focused radiation therapy (called SBRT-Lattice) for large tumors in patients who can't benefit from surgery, chemotherapy, or standard radiation. The radiation uses a lattice pattern designed to treat the tumor while protecting healthy tissue nearby.
São Paulo, São PauloAges 18 years+ - NCT06690528RecruitingPhase 2
Surgery vs. palliative care for pancreatic cancer with limited liver spread
This trial compares surgery to remove the primary tumor and up to 3 liver spots against standard palliative care for people with pancreatic cancer that has spread only to the liver (up to 3 spots). It is for those whose cancer has not grown after initial chemotherapy and who are healthy enough for surgery.
Padova, ItalyAges 18–75 - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT05979818RecruitingPhase 1
Propranolol plus immunotherapy and chemo for advanced lung cancer
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Changsha, HunanAges 18–75 - NCT07637448RecruitingPhase 2
EGFR-targeted therapy plus immunotherapy for advanced lung cancer
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18 years+ - NCT07636798RecruitingPhase 1/Phase 2
Chemotherapy and immunotherapy combination for advanced bile duct cancer
This trial tests a combination of three treatments—chemotherapy delivered directly to the liver, plus two immunotherapy drugs—for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment and is safe for patients.
Chengdu, SichuanAges 18–75 - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT07619235RecruitingPhase 4
Combination immunotherapy and chemotherapy for advanced bile duct cancer
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
Wuhan, HubeiAges 18–75 - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+ - NCT07618260RecruitingPhase 1
Testing SIM0613 in advanced solid tumors
This is an early-stage trial testing a new drug called SIM0613 for advanced cancers that have spread or grown despite other treatments. The drug is designed to target cancer cells using a special delivery system.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 4,281 recruiting locally advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced/Metastatic Breast Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Advanced or Metastatic Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.